Kymera Therapeutics, Inc. (KYMR)
| Market Cap | 8.80B +183.8% |
| Revenue (ttm) | 51.48M -12.6% |
| Net Income | -315.00M |
| EPS | -3.55 |
| Shares Out | 82.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 444,443 |
| Open | 105.66 |
| Previous Close | 105.25 |
| Day's Range | 104.32 - 107.82 |
| 52-Week Range | 36.65 - 130.05 |
| Beta | 1.96 |
| Analysts | Strong Buy |
| Price Target | 127.18 (+18.85%) |
| Earnings Date | Aug 5, 2026 |
About KYMR
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid... [Read more]
Financial Performance
In 2025, Kymera Therapeutics's revenue was $39.21 million, a decrease of -16.70% compared to the previous year's $47.07 million. Losses were -$311.35 million, 39.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for KYMR stock is "Strong Buy." The 12-month stock price target is $127.18, which is an increase of 18.85% from the latest price.
News
Kymera Therapeutics initiated with a Hold at Deutsche Bank
Deutsche Bank initiated coverage of Kymera Therapeutics (KYMR) with a Hold rating and $120 price target Kymera is the leader in the field of targeted protein degradation, with a proprietary…
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
WATERTOWN, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Kymera Therapeutics price target raised to $135 from $125 at Guggenheim
Guggenheim raised the firm’s price target on Kymera Therapeutics (KYMR) to $135 from $125 and keeps a Buy rating on the shares. Kymera could gain significant value if KT-579’s 2026…
Kymera Therapeutics CMO Jared Gollob to retire, Terence Rooney to succeed
Kymera Therapeutics (KYMR) announced the appointment of Terence Rooney as chief medical officer. Rooney is an accomplished drug development leader with extensive experience advancing immunology therap...
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera's industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his rol...
Kymera Therapeutics price target raised to $140 from $120 at Mizuho
Mizuho analyst Joseph Catanzaro raised the firm’s price target on Kymera Therapeutics (KYMR) to $140 from $120 and keeps an Outperform rating on the shares. The firm cites the acceleration…
Kymera Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Brian Abrahams downgraded Kymera Therapeutics (KYMR) to Sector Perform from Outperform with a price target of $115, up from $106. While the firm believes STAT6 degrader ‘621…
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026...
Kymera Therapeutics price target raised to $125 from $110 at BofA
BofA raised the firm’s price target on Kymera Therapeutics (KYMR) to $125 from $110 and keeps a Buy rating on the shares. Following the announcement last week that enrollment in…
Kymera Therapeutics price target raised to $155 from $117 at B. Riley
B. Riley raised the firm’s price target on Kymera Therapeutics (KYMR) to $155 from $117 and keeps a Buy rating on the shares. The company unexpectedly announced completing BROADEN2 Phase…
Kymera Therapeutics price target raised to $136 from $116 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Kymera Therapeutics (KYMR) to $136 from $116 and keeps a Buy rating on the shares. Kymera is viewed positively following…
Kymera Therapeutics price target raised to $129 from $106 at Canaccord
Canaccord analyst Edward Nash raised the firm’s price target on Kymera Therapeutics (KYMR) to $129 from $106 and keeps a Buy rating on the shares. The firm said Kymera announced…
Kymera Therapeutics Stock (KYMR) Soars on Accelerated Clinical Trial Enrollment
Kymera Therapeutics stock gained on Thursday after the company revealed quick enrollment in a clinical trial.
Biotech ETF Index Surges 10% After Rebalance
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underly...
Kymera Therapeutics rises 18.6%
Kymera Therapeutics (KYMR) is up 18.6%, or $18.58 to $118.45.
Kymera Therapeutics completes enrollment in BROADEN2 trial
Kymera Therapeutics (KYMR) announced it has completed enrollment in the global BROADEN2 Phase 2b trial of KT-621, its first-in-class, oral STAT6 degrader, for the treatment of moderate to severe atopi...
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expec...
Kymera Therapeutics appoints Felix Baker as chairman
Kymera Therapeutics (KYMR) announced the appointment of Felix Baker as chairman of the board of directors. Baker succeeds Bruce Booth, DPhil, who has served as chairman since co-founding Kymera in…
Kymera Therapeutics Appoints Felix J. Baker, Ph.D.
Bruce Booth, DPhil, Co-Founder and Chairman, to remain an Independent Director WATERTOWN, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmac...
Kymera Therapeutics Transcript: AGM 2026
The meeting covered board introductions, three shareholder proposals, and voting procedures. All proposals—including director elections, executive compensation approval, and auditor ratification—were passed. No questions were raised by shareholders.
Kymera Therapeutics participates in a conference call with JPMorgan
JPMorgan holds a conference call with management on June 17 at 2 pm. Webcast Link
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, In...
Kymera Therapeutics Slides: Corporate presentation
Kymera Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.